| BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors M Gonzalez-Cao, C Mayo-De-Las-Casas, MA Molina-Vila, ... Melanoma research 25 (6), 486-495, 2015 | 89 | 2015 |
| Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial T Powles, SS Sridhar, Y Loriot, J Bellmunt, XJ Mu, KA Ching, J Pu, ... Nature Medicine 27 (12), 2200-2211, 2021 | 75 | 2021 |
| FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC/FAK/RHO/ROCK-dependent pathway J Tornin, F Hermida-Prado, RS Padda, MV Gonzalez, ... Neoplasia 20 (1), 44-56, 2018 | 41 | 2018 |
| Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer … JF Rodriguez-Moreno, G de Velasco, I Bravo Fernandez, ... Journal of Clinical Oncology 38 (6_suppl), 542-542, 2020 | 40 | 2020 |
| New Chondrosarcoma Cell Lines with Preserved Stem Cell Properties to Study the Genomic Drift During In Vitro/In Vivo Growth V Rey, ST Menendez, O Estupiñan, A Rodriguez, L Santos, J Tornin, ... Journal of clinical medicine 8 (4), 455, 2019 | 24 | 2019 |
| Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma PJ Fonseca, E Uriol, JA Galván, C Álvarez, Q Pérez, N Villanueva, ... Case Reports in Oncology 6 (2), 441-449, 2013 | 24 | 2013 |
| The multikinase inhibitor EC‐70124 synergistically increased the antitumor activity of doxorubicin in sarcomas O Estupiñan, L Santos, A Rodriguez, L Fernandez‐Nevado, P Costales, ... International journal of cancer 145 (1), 254-266, 2019 | 15 | 2019 |
| 699O Avelumab first-line (1L) maintenance+ best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory … TB Powles, Y Loriot, J Bellmunt, CN Sternberg, S Sridhar, DP Petrylak, ... Annals of Oncology 31, S552-S553, 2020 | 13 | 2020 |
| Orbital metastases in colorectal cancer: a case report M Garcia-Fernandez, J Castro-Navarro, A Saiz-Ayala, ... Archivos de la Sociedad Española de Oftalmología (English Edition) 87 (7 …, 2012 | 10 | 2012 |
| Results from the INMUNOSUN-SOGUG trial: A prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune … E Grande, T Alonso-Gordoa, O Reig, E Esteban, D Castellano, ... ESMO open 7 (2), 100463, 2022 | 8 | 2022 |
| Avelumab first-line (1L) maintenance+ best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): association between clinical outcomes and exploratory … S Sridhar, TB Powles, Y Loriot, J Bellmunt, CN Sternberg, DP Petrylak, ... Ann Oncol 31 (suppl_4), S550-S550, 2020 | 8 | 2020 |
| 761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer … JF Rodriguez-Moreno, G De Velasco, C Alvarez-Fernandez, R Collado, ... Annals of Oncology 31, S589, 2020 | 7 | 2020 |
| Plaque Psoriasis Flare and Peripheral Edema in a Patient Treated With Atezolizumab J Santos-Juanes, P Munguía Calzada, C Álvarez Fernández Actas Dermosifiliogr (Engl Ed) 110 (5), 410-411, 2018 | 7 | 2018 |
| Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours MF Sanmamed, E Esteban, E Uriol, R Zarate, M Capelan, C Muriel, ... Journal of Translational Medicine 15 (1), 1-9, 2017 | 7 | 2017 |
| Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC) C Alvarez-Fernandez, Q Perez-Arnillas, L Ruiz-Echeverria, ... Investigational new drugs 32, 377-381, 2014 | 7 | 2014 |
| Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC). C Alvarez Fernandez, Q Perez Arnillas, AL Ruiz, DJ Rodriguez Rubi, ... Journal of Clinical Oncology 31 (15_suppl), e19034-e19034, 2013 | 7 | 2013 |
| Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial … S Vazquez-Estevez, O Fernandez-Calvo, T Bonfill-Abella, S Sequero, ... Journal of Clinical Oncology 40 (16_suppl), 4588-4588, 2022 | 5 | 2022 |
| Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer … JF Rodriguez-Moreno, E Sevillano, MD Fenor, R Collado Martín, ... Journal of Clinical Oncology 37 (7_suppl), TPS503-TPS503, 2019 | 5 | 2019 |
| Metástasis orbitarias en carcinoma colorrectal: a propósito de un caso M García-Fernández, J Castro-Navarro, A Saiz-Ayala, ... Archivos de la Sociedad Española de Oftalmología 87 (7), 216-219, 2012 | 4 | 2012 |
| Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial. JF Rodriguez-Moreno, S Ruiz-Llorente, G De Velasco, ... Journal of Clinical Oncology 40 (6_suppl), 546-546, 2022 | 3 | 2022 |
Aurora Astudillo GonzálezProfesor de Anatomía PatológicaVerified email at hca.es
